Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Jul;174(3):376-80.
doi: 10.1007/s00213-003-1763-9. Epub 2004 Mar 2.

A comparison of d, l-fenfluramine and citalopram challenges in healthy adults

Affiliations
Comparative Study

A comparison of d, l-fenfluramine and citalopram challenges in healthy adults

Janine D Flory et al. Psychopharmacology (Berl). 2004 Jul.

Abstract

Dimensional personality characteristics (e.g. impulsivity) and related behaviors and psychiatric disorders are linked to abnormalities of central nervous system (CNS) serotonergic functioning. Although neuroendocrine [e.g. plasma prolactin (PRL)] responses to the serotonin agonist, fenfluramine, have been used widely to index CNS serotonergic responsivity, safety concerns constrain continued use of fenfluramine. Citalopram, which inhibits serotonin reuptake, may serve as an alternative pre-synaptic neuropharmacologic challenge agent, due to its high selectivity and absence of intrinsic activity at serotonin or other receptor families. Twenty-two healthy adults who had been administered a fenfluramine challenge before May 1996 completed a 5-h oral citalopram challenge 3-6 years later. PRL responsivity to citalopram correlated significantly with PRL response to fenfluramine for baseline-corrected maximal and area-under-the-curve (AUC) indices ( r's > or =0.49, P's< or =0.02). The magnitude of the correlations is notable given the length of time between challenges. The results support the use of citalopram as an alternate neuroendocrine challenge to index CNS serotonergic responsivity.

PubMed Disclaimer

References

    1. Int J Neuropsychopharmacol. 2002 Mar;5(1):67-71 - PubMed
    1. Biol Psychiatry. 1990 May 15;27(10):1143-55 - PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Nov;20(8):1315-23 - PubMed
    1. Br J Psychiatry. 2002 Jan;180:24-8 - PubMed
    1. Psychopharmacology (Berl). 2001 May;155(3):323-6 - PubMed

Publication types

LinkOut - more resources